Neurology: Correlation between pre-stroke metformin use, stroke severity and thrombolytic outcome

Recently, a study published in the journal Neurology, the study aims to assess whether the pretreatment ofmetformin(MET) is related to lowerstrokeseverity and better venous thrombolysis (IVT) prognosis, and the researchers analyzed 1919diabetesstroke patients in a multicenter exploratory studyin collaboration with ischemic stroke patients in Europe (TRISP), researchers collected data on patients with ischemic stroke who received IVT therapy and applied prifity score matching (PSM) to obtain baseline characteristics in patients receiving and not receiving MET treatmentof 1919 cases of stroke with type 2 diabetes who received IVT, 757 (39%) received MET before stroke, while 1,162 (61%) were not met treatment (MET-)Met plus patients are predominantly malePretreatment of highcholesteroland statins, antiplatelets, or antihypertensivedrugs is more common in the MET-plus groupAfter PSM, both groups maintained a good demographic and clinical balanceStroke severity at admission (NIHSS 10.0-6.7 vs11.3-6.5), improved Rankin scale (mRS) for 3 months independence: 2 (IQR 1.0, 4.0) vs 3 (IQR 1.0, 4.0) and mortality (12.5% vs 18%) significantly reduced in the MET-plus group There was no difference in the frequency of symptomatic cerebral haemorrhage between the two groups, and the HbA1c level was well balanced it can be seen that diabetic stroke patients treated with MET received IVT treatment after admission to the hospital stroke severity is less severe, and 3 months of function prognosis is better This indicates that MET has a stroke protection effect